

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB05/000806

International filing date: 02 March 2005 (02.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: GB  
Number: 0404693.4  
Filing date: 02 March 2004 (02.03.2004)

Date of receipt at the International Bureau: 09 May 2005 (09.05.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

I also certify that the attached copy of the request for grant of a Patent (Form 1/77) bears a correction, effected by this office, following a request by the applicant and agreed to by the Comptroller-General.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated 21 April 2005





11 5777041 000001  
03MAR04 001/770000,00-0404693/4 NONE

The Patent Office

Cardiff Road  
Newport  
South Wales  
NP10 8QQ

## Request for grant of a patent

(See the notes on the back of this form. You can also get  
an explanatory leaflet from the Patent Office to help you fill in  
this form)

1. Your reference 9540 GB JSvn/TJH

2. Patent application number  
(The Patent Office will fill this part in)

0404693.4

- 2 MAR 2004

3. Full name, address and postcode of the or of  
each applicant (underline all surnames)

Institute of Ophthalmology & Moorfields Eye Hospital  
University College London NHS Trust  
11-43 Bath Street City Road  
London EC1V 9ELN London EC1V 2PD

Patents ADP number (if you know it)

7400104002

8821118001

If the applicant is a corporate body, give the  
country/state of its incorporation

U.K.

U.K.

4. Title of the invention Pharmaceutical preparations for the treatment of ocular surface and other disorders

5. Name of your agent (if you have one) Abel &amp; Imray

"Address for service" in the United Kingdom  
to which all correspondence should be sent  
(including the postcode)

20 Red Lion Street  
London  
WC1R 4PQ  
United Kingdom

Patents ADP number (if you know it) 174001

6. Priority: Complete this section if you are  
declaring priority from one or more earlier  
patent applications, filed in the last 12 months.

Country

Priority application number  
(if you know it)Date of filing  
(day / month / year)7. Divisionals, etc: Complete this section only if  
this application is a divisional application or  
resulted from an entitlement dispute (see note f)Number of earlier UK application  
(day / month / year)8. Is a Patents Form 7/77 (Statement of  
inventorship and of right to grant of a patent)  
required in support of this request?

Yes

Answer YES if:

- any applicant named in part 3 is not an inventor, or
- there is an inventor who is not named as an applicant, or
- any named applicant is a corporate body.

Otherwise answer NO (See note d)

9. Accompanying documents: A patent application must include a description of the invention. Not counting duplicates, please enter the number of pages of each item accompanying this form:

Continuation sheets of this form

Description 51

Claim(s) 5

Abstract

Drawing(s)

---

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for a preliminary examination and search (Patents Form 9/77)

Request for a substantive examination (Patents Form 10/77)

Any other documents (please specify)

---

11. I/We request the grant of a patent on the basis of this application.

Signature(s)

*Abel & Imray*

Date 2 March 2004

---

12. Name, daytime telephone number and e-mail address, if any, of person to contact in the United Kingdom

Tim Hewson

01225 469914

#### Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

#### Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered YES in part 8, a Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) Part 7 should only be completed when a divisional application is being made under section 15(4), or when an application is being made under section 8(3), 12(6) or 37(4) following an entitlement dispute. By completing part 7 you are requesting that this application takes the same filing date as an earlier UK application. If you want the new application to have the same priority date(s) as the earlier UK application, you should also complete part 6 with the priority details.

PHARMACEUTICAL PREPARATIONS FOR AND TREATMENT OF  
OCULAR SURFACE AND OTHER DISORDERS

**INTRODUCTION**

5 The present invention relates to pharmaceutical preparations and their use in the treatment and/or prophylaxis of dry eye conditions and other ocular surface disorders.

**BACKGROUND OF THE INVENTION**

10 Integrity of the ocular surface is essential for visual acuity and ocular protection. Ocular surface disorders are a group of diseases and disorders of diverse pathogenesis, which result from the failure of the mechanisms responsible for maintaining a healthy ocular surface. Any condition or 15 disorder in which the ocular surface is not a properly functioning unit is an ocular surface disorder.

The causes of ocular surface disorder may be nutritional, traumatic, iatrogenic, proliferative, may be secondary to lid 20 abnormalities, may be caused by abnormal tear film, or may be neurotrophic. Trauma may be physical, chemical or thermal. Ocular surface disorders are often resistant to therapy. Some types of ocular surface disorders result from or cause dry or severely dry eyes, a condition also known as 25 keratoconjunctivitis sicca. However, dry eye conditions may occur without causing or resulting from ocular surface disorders.

Two basic types of dry eye conditions are generally 30 recognised, namely "tear deficient" dry eye, also known as "evaporative" dry eye, in which fewer tears are produced than by normal eyes, and "tear sufficient" dry eye, in which the volume of tears produced is apparently normal or approximately normal, but the constitution of the tears is

such that they do not function properly. The most common cause of tear sufficient dry eye is meibomian gland disease. The meibomian glands secrete lipids that affect the surface tension of the tears and hence their ability to wet the 5 surface of the eye. In the absence of sufficient and/or suitable lipids the tears do not fulfil their function properly.

Tear deficient dry eye conditions include both Sjögren's dry 10 eye and non-Sjögren's dry eye. When part of Sjögren's syndrome, dry eye condition is often severe. Non-Sjögren's dry eye is very common. Dry eye conditions, even when not associated with other pathologies, cause much discomfort and pain and predispose the eye to infection and may, in rare 15 cases, cause corneal melting.

A wide variety of treatments have been proposed for ocular surface disorders and dry eye conditions. Such treatments include topical therapy, surgery and therapeutic contact 20 lenses. Current commercially available preparations for tear replacement therapy are ocular lubricants, which can improve tear volume and hydrodynamics. They are generally composed of electrolytes, water and agents that increase retention time on the ocular surface.

25

#### **SUMMARY OF THE INVENTION**

The present invention provides a pharmaceutical preparation suitable for use in the eye, which comprises

(i) a pharmaceutically carrier suitable for use in the eye; 30 (ii) one or more ingredients selected from factors and agents that promote any one or more of survival, health, cell attachment and normal differentiation of ocular surface epithelial cells and optionally factors and agents that prevent squamous metaplasia;

(iii) one or more agents capable of altering the fluid properties of a tear film including at least one agent capable of establishing and/or maintaining a stable tear film and including one or more agents selected from

5 ophthalmological lubricating agents, viscosity enhancing agents and agents capable of reducing tear film evaporation; the factors and agents in components (ii) and (iii) being synthetic or recombinant or licensed for pharmaceutical use.

10 This pharmaceutical preparation is called herein "an ocular surface medium" or "OS Medium".

An ocular surface medium of the invention may also comprise

15 (iv) one or more agents suitable for use in the treatment of an ocular surface disease, disorder or damage.

Such a preparation is called herein "a therapeutic ocular surface medium" or "TOS Medium".

20 A pharmaceutical preparation of the invention comprising components (i), (ii) and (iii) may further comprise (v) one or more ingredients selected from factors and agents that promote any one or more of survival and maintenance of stem cell characteristics, growth of ocular surface stem cells, 25 and survival, maintenance and differentiation of stem cell offspring in vitro or in vivo, the factors and agents being synthetic or recombinant or licensed for pharmaceutical use.

Such a preparation is called herein "a limbal stem cell 30 medium" or "LSC Medium".

A limbal stem cell medium of the invention, comprising components (i), (ii), (iii) and (v) may further comprise (iv)

one or more agents suitable for use in the treatment of an ocular surface disease, disorder or damage.

Such a preparation is called herein "a therapeutic limbal 5 stem cell therapeutic medium" or "TLSC Medium".

Unless specified otherwise, the term "a pharmaceutical preparation of the present invention" is used herein generically to denote any preparation of the invention, that 10 is to say, an ocular surface medium of the invention, a therapeutic ocular surface medium of the invention, a limbal stem cell medium of the invention and a therapeutic limbal stem cell medium of the invention.

15 The present invention also provides a pharmaceutical preparation of the invention for use as a medicament, for example, for use in treatment or prophylaxis of a dry eye condition or an ocular surface disorder. An ocular surface medium or therapeutic ocular surface medium of the invention 20 may be used.

The present invention also provides a method for treatment or prophylaxis of a dry eye condition or an ocular surface disorder in a subject, which comprises administering a 25 therapeutically effective amount of a pharmaceutical preparation of the invention to the affected eye of the subject. An ocular surface medium or therapeutic ocular surface medium of the invention may be used.

30 The present invention also provides a pharmaceutical preparation of the invention, in particular a limbal stem cell medium or a therapeutic limbal stem cell medium of the invention, for use in treatment or prophylaxis of a condition involving a deficiency or failure of limbal stem cells, or

for post-operative therapy following surgery for limbal stem cell transplantation.

The present invention further provides a method for use in  
5 treatment or prophylaxis of a condition involving a deficiency or failure of limbal stem cells in an eye of a subject, or for post-operative therapy following surgery for limbal stem cell transplantation in an eye of a subject, which comprises administering a therapeutically effective  
10 amount of a pharmaceutical preparation of the invention, for example, a limbal stem cell medium or a therapeutic limbal stem cell medium of the invention, to the affected eye of the subject.

15 The present invention provides the use of an ocular surface medium or limbal stem cell medium of the present invention as a pharmaceutical vehicle or carrier for an ophthalmological pharmaceutical composition.

20 The present invention also provides a ophthalmological pharmaceutical composition that comprises a therapeutic agent and, as the or a pharmaceutical vehicle or carrier, an ocular surface medium or limbal stem cell medium of the present invention.

25 The present invention also provides a method of treating an ocular surface disorder in a subject in need of such a treatment comprising administering a therapeutically effective amount of a pharmaceutical preparation of the  
30 invention.

Preferably the ocular surface disorder is selected from scaring, ocular pemphigoid, persistent epithelial defect, acute ocular surface disorder, chronic ocular surface

disease, infection or inflammation of the eye, neoplastic conditions of the eye and trauma to the eye.

Preferably said subject is a mammal. Preferably the mammal  
5 is a human. Alternatively the mammal may be a non-human animal. Non-human animals include animals raised for food, transport, hides, hair or fleece, for example, cattle, horses, sheep, goats, pigs; animals used for the production of a pharmaceutically useful agent, for example, recombinant 10 proteins; stud and breeding animals; racehorses; and companion animals, for example, cats, dogs and small mammals.

Alternatively said subject may be a bird, for example, a bird raised for food or as a companion animal.

15

#### **DEFINITIONS**

The following terms used herein have meanings given below:

*Cell attachment:* Cell attachment means adhesion of cell to  
20 each other and to the basement membrane.

*Dry eye condition and dry eye:* The terms "dry eye condition" and "dry eye" are used herein to include all conditions characterised by deficient and/or defective tears. In such 25 conditions the ocular surface is subjected to an aqueous deficiency. Dry eye may range from mild to severe, and may or may not be part of an ocular surface disorder or another disease condition. Some types of ocular surface disorders result from or cause dry or severely dry eyes, a condition 30 also known as keratoconjunctivitis sicca. However, dry eye conditions may occur without causing or resulting from ocular surface disorders.

Growth: The term "growth" when used to describe a process that continues over a long period of time, generally implies an increase in total mass and volume accompanied by a proportional increase in number of cells. On a short term basis, the term "growth" can describe an increase in cell size (mass and volume) with no change in cell number.

Growth factor: Growth factor means a non-nutritive substance that does not participate in biosynthesis, metabolism or catalysis, but instead controls proliferation in a regulative manner.

Growth requirement: Growth requirement refers to anything that has a positive effect on cell multiplication.

15

Health: Health means the maintenance of the normal characteristics and function of the cell, and also maintenance of the cell phenotype.

20 Hormones: Hormones are chemical substances that are transmitted through body fluids and affect target cells at locations remote from the cells that produce them.

Multiplication and proliferation: Multiplication and proliferation both imply a net increase in cell number, with a corresponding increase in total mass and volume, such that both daughter cells become essentially identical to their parent cell.

30 Normal cells: Normal cells are cells that do not differ in any significant way from cells found in a healthy intact organism.

*Normal differentiation:* Normal differentiation means differentiation to the normal cell end point.

*Nutrient:* Nutrient refers to a chemical substance that is 5 taken into a cell and utilised as a substrate in biosynthesis or energy metabolism, or else as a catalyst in one of those processes.

*Ocular surface disorder:* Any condition or disorder in which 10 the ocular surface is not a properly functioning unit is an ocular surface disorder. Ocular surface disorders include diseases and disorders of diverse pathogenesis, which result from the failure of mechanisms responsible for maintaining a healthy ocular surface. The cause of an ocular surface 15 disorder may be nutritional, iatrogenic, proliferative, may be secondary to lid abnormalities, or may be neurotrophic. Ocular surface disorders may result from damage to the ocular surface, for example, by surgery, by accidental trauma including physical, chemical and thermal trauma, by scarring, 20 and also includes ocular pemphigoid. Some types of ocular surface disorders result from or cause dry or severely dry eyes.

*Survival:* "Survival" refers specifically to the maintenance 25 of viability. In most case, survival implies retention of the ability to respond by multiplication when all growth requirements are satisfied.

*Survival requirement:* Survival requirement refers to any 30 member of the set of minimal environmental conditions that must be provided in order for the cells in question to remain fully viable.

5 *Synthetic and recombinant factors and agents:* Synthetic and recombinant factors and agents are substances that have been produced by chemical synthesis or by recombinant DNA technology i.e. they have not been obtained from natural sources.

10 *Tear break-up time (BUT):* Tear break-up time (BUT) is the interval between a complete blink and the appearance of the first dry step on the conjugal surface.

#### **DETAILED DESCRIPTION OF THE INVENTION**

##### **Pharmaceutical preparations of the invention**

As stated above, the present invention provides a pharmaceutical preparation suitable for use in the eye, which 15 comprises

- (i) a pharmaceutically carrier suitable for use in the eye;
- (ii) one or more ingredients selected from factors and agents that promote any one or more of survival, health, cell attachment and normal differentiation of ocular surface epithelial cells and, optionally, from factors and agents that prevent squamous metaplasia;
- (iii) one or more agents capable of altering the fluid properties of a tear film including at least one agent capable of establishing and/or maintaining a stable tear film; and, optionally one or more agents selected from ophthalmological lubricating agents, viscosity enhancing agents and agents capable of reducing tear film evaporation; the factors and agents in components (ii) and (iii) being synthetic or recombinant or licensed for pharmaceutical use.

30 This embodiment of the invention is called "an ocular surface medium" or "OS Medium". Suitable carriers (i) and factors and agents for use in components (ii) and (iii) are described and

exemplified in the section "Ingredients of pharmaceutical preparations of the invention" below.

An ocular surface medium of the invention may also comprise

5 (iv) one or more agents suitable for use in treatment or prophylaxis of an ocular surface disorders or damage in addition to components (i) to (iii). Agents suitable for use in treatment or prophylaxis of ocular surface disorders include, for example, mydriatics, steroids, mucolytic agents,

10 inhibitors of angiogenesis, antifibrotic agents, antimicrobial agents, and agents that reduce the accumulation of toxic by-products at the ocular surface. Further examples of agents suitable for use in component (v) are given in "Ingredients of pharmaceutical preparations of the invention"

15 below.

A pharmaceutical preparation of the invention comprising components (i), (ii) and (iii) may further comprise (v) one or more ingredients selected from factors and agents that

20 promote any one or more of survival and maintenance of stem cell characteristics, growth of ocular surface stem cells, and survival, maintenance and differentiation of stem cell offspring *in vitro* or *in vivo*.

25 Such a preparation is called herein "a limbal stem cell medium" or "LSC Medium". Examples of ingredients suitable for use in component (v) are given in "Ingredients of pharmaceutical preparations of the invention" below.

30 A limbal stem cell medium of the invention, comprising components (i), (ii), (iii) and (v), may further comprise (iv) one or more agents suitable for use in treatment or prophylaxis of an ocular surface disorder.

Such a preparation is called herein "a therapeutic limbal stem cell therapeutic medium" or "TLSC Medium".

Limbal stem cells, which occur in the limbus tissue at the junction of the cornea and the conjunctiva and/or in the fornix, are the progenitors of the epithelial cells of the conjunctiva and cornea ie the ocular surface. Even partial failure of these stem cells to maintain healthy, normally differentiated ocular surface epithelial cells has severe consequences for the ocular surface.

**Ingredients of pharmaceutical preparations of the invention**

**Component (i):** Component (i) of the pharmaceutical preparations of the invention is a pharmaceutically carrier suitable for use in the eye. Carriers suitable for use in the eye are well known and are described in pharmacopoeiae. They include suitably purified water for eye drops, and cream, gel and ointment bases for ophthalmological compositions. For example, carbomers are often used as bases for gels, and paraffin and/or lanolin for ointments. The carrier may comprise one or more agents selected from tonicity agents for example, glucose; and buffering agents for example HEPES or bicarbonate.

**Component (ii):** All the pharmaceutical preparations of the present invention comprise one or more ingredients selected from factors and agents that promote any one or more of survival, maintenance, health, growth, migration, cell attachment and normal differentiation of epithelial cells and, optionally, that prevent squamous metaplasia.

Such agents may be selected from agents that provide metabolisable source of carbon, amino acids, growth factors, vitamins, antioxidants, mucin substitutes, bulk ions, trace

elements, proteins and hormones, protease inhibitors, and anti-microbial agents.

Preferred ingredients in the various categories above are 5 given below. Any selection of one or more ingredients from each category may be used, and any combination of ingredients may be used. Preferably, a selection of ingredients includes at least one ingredient from each category.

10 Metabolisable source of carbon

Glucose, pyruvate, preferably glucose.

Amino acids

Preferably all of the essential amino acids and, optionally, 15 one or more of the non-essential amino acids, amino acids preferably being L-amino acids:

*Essential amino acids:* Arginine, Cysteine, Glutamine, Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Threonine, Tryptophan, Valine

20 *Non-essential amino acids:* Alanine, Glycine, Asparagine, Aspartic acid, Glutamic acid, Proline, Serine, Tyrosine

Growth factors

EGF (epithelial growth factor), HGF (hepatocyte growth 25 factor), KGF (keratinocyte growth factor), NGF (neuronal growth factor), glial-derived neurotrophic factor, neurotrophins.

Antimicrobial agents

30 Lactoferrin, lysozyme, defensins, secretory Immunoglobulin A

Hormones

Insulin

Vitamins

Vitamin C (ascorbic acid and salts thereof), and optionally any one or more of biotin, folic acid, lipoic acid, niacinamide, pantothenate, pyridoxine, riboflavin, thiamine, 5 vitamin B12 and vitamin A.

Antioxidants

Tyrosine and/or glutathione.

10 Mucin substitutes

Synthetic mucin substitutes and/or hyaluronic acid

Electrolytes

Comprising one or more electrolyte selected from bulk ions, 15 for example, any one of more of sodium, potassium, calcium, chloride, bicarbonate, nitrate, sulphate, magnesium, and phosphate ions; and trace elements, for example, any one or more of copper, iron, manganese, molybdenum, nickel, selenium, silicon, tin, vanadium, and zinc

20

Organic compounds

Any one or more of adenine, choline, i-inositol, linoleate, putrescine, pyruvate, and thymidine.

25 Protease inhibitors

Any one or more of tissue inhibitors of matrix metalloproteases (TIMPs),  $\alpha$ 1-antitrypsin,  $\alpha$ 2-macroglobulin, inter- $\alpha$ -antitrypsin, and  $\alpha$ 1-chymotrypsin.

30 Attachment factors

Fibronectin

Agents that reduce the accumulation of toxic byproducts of cell metabolism

Chelators, free-radical scavengers.

In component (ii), a pharmaceutical preparation of the invention should generally comprise a metabolisable source of 5 carbon, which is preferably glucose. Glucose is generally present at a concentration of from about 20 to about 1500 mg/l, preferably at about 26 mg/ml.

Lactoferrin is preferably present, for example, at a 10 concentration of from about 0.2 to about 4 mg/ml, for example, about 1.5 mg/ml.

Lysozyme is a further preferred ingredient present at a concentration of about 0.2 to about 7.0 mg/ml more preferably 15 at a concentration of about 0.4 to about 3.5 mg/ml, for example, about 1.5 mg/ml.

Vitamin C is preferably present, for example, at a concentration of from about 100 to about 500  $\mu$ g/ml, for 20 example, about 117  $\mu$ g/ml for an ocular surface medium or a limbal surface medium and about 500  $\mu$ g/ml for a therapeutic ocular surface medium.

Vitamin A is generally present. For an ocular surface medium 25 or for a limbal surface medium the concentration is, for example, about from 10 to 20 ng/ml, for example, about 15 ng/ml. For a therapeutic ocular surface medium or a therapeutic limbal surface medium, the concentration is preferably higher, for example, a concentration of about 30 0.5mg/ml would be suitable for use in a therapeutic medium for the treatment of alkali injury.

Epidermal growth factor is preferably present, for example, in a concentration of from about 0.1 to about 2 ng/ml, for example, about 1 ng/ml.

5 Tyrosine is preferably present, for example, in a concentration of from about 40 to about 100  $\mu$ Molar, for example, at about 62  $\mu$ Molar.

10 Glutathione is preferably present in addition to or as an alternative to tyrosine, for example, in a concentration of from about 50 to about 110  $\mu$ Molar.

15 Sodium ions are preferably present, for example, in an amount of from about 140 to about 150 mEq/litre, for example, about 145 mEq/litre.

Potassium ions are preferably present, for example, in an amount of from about 20 to about 30 mEq/litre, for example, from about 24 to about 25 mEq/litre.

20 Calcium, chlorine, bicarbonate, nitrate, phosphate and sulphate ions are preferably present, calcium ions at a concentration of about 1.0 to about 2.0 mM, for example, about 1.5 mM, chlorine ions at a concentration of from about 25 120 to about 130 mM, for example, about 128 mM, bicarbonate ions at a concentration of from about 20 to about 30 mM, for example, about 26 mM, nitrate ions at a concentration of about 0.1 to about 0.2 mM, for example, from about 0.13 to about 0.14 mM, phosphate ions at a concentration of from 30 about 0.15 to about 0.25 mM, for example, from about 0.20 to about 0.24 mM, and sulphate ions at a concentration of from about 0.35 to about 0.45 mM, for example, from about 0.38 to about 0.40 mM.

It may be advantageous for a preparation of the invention to comprises all the ingredients listed in this section, ie glucose, lactoferrin, lysozyme, EGF, tyrosine, glutathione, vitamin C, vitamin A and sodium, potassium, calcium, 5 bicarbonate, nitrate, phosphoric and sulphate ions. The concentrations are preferably as set out above.

*Component (iii):* Component (iii) of a pharmaceutical preparation of the present invention comprises one or more 10 agents capable of altering the fluid properties of a tear film including at least one agent capable of establishing and/or maintaining a stable tear film and optionally one or more agents selected from ophthalmological lubricating agents, viscosity enhancing agents and agents capable of 15 reducing tear film evaporation.

Agents capable of establishing and/or maintaining a stable tear film are known in the art and include various lipids, preferably polar lipids, for example sphingomyelin and 20 phosphatidylcholine, and lipoproteins, for example, ethanolamine and phosphoethanolamine. Alternatively or in addition meibomian gland secretions, or synthetic analogues thereof, or one or more components thereof may be used.

Meibomian gland secretions include the protein lipocalin, 25 which is an agent involved in establishing and/or maintaining a stable tear film.

Ophthalmological lubricating agents, viscosity enhancing agents and agents capable of reducing tear film evaporation 30 are also known in the art and include, for example, hypromellose, semisynthetic cellulose derivatives, methylcellulose, hydroxypropylmethylcellulose, carbomer, carmellose, polyvinyl alcohol, polyacrylic acid, povidone,

dextran solutions, and viscoelastic agents, for example, hyaluronic acid and chondroitin sulphate.

*Component (iv):* The optional component (iv) of a pharmaceutical preparation of the present invention comprises one or more agents suitable for use in treatment or prophylaxis of ocular surface disease, disorders or damage. Such agent include, for example, isoproterenol; corticosteroids, for example, hydrocortisone and dexamethasone; non-sterodial anti-inflammatory agents; mucolytic agents, for example, acetylcysteine; inhibitors of angiogenesis, for example, angiostatin, angiotensin and anti-VEGF; attachment factors, for example, fibronectin; antifibrotic agents, for example, anti-TGF $\beta$ ; antimicrobial agents, for example, antibiotics, defensins, disinfectants, and antimicrobial agents found in normal tears, for example, lysozyme, lactoferrin and sIgA; and agents that reduce the accumulation of toxic byproducts of cell metabolism, for example, chelators, free-radical scavengers and anti-oxidents, protease inhibitors, for example, matrix metalloprotease inhibitors,  $\alpha$ 1-antitrypsin,  $\alpha$ 2-macroglobulin, inter- $\alpha$ -trypsin, and  $\alpha$ 1-chymotrypsin; and vitamin A.

A pharmaceutical preparation of the present invention preferably does not contain a preservative, especially not benzalkonium chloride, which is toxic to ocular surface cells. The incorporation of anti-microbial agents, for example, any one or more of lactoferrin, lysozyme, defensins and sIgA ensures the preparation can be used for the normal period of one month without microbial contamination, provided that the usual standards of hygiene are maintained. A non-preserved preparation is preferably stored at about 4°C e.g. in a refrigerator.

Component (v): Component (v), which is present in the limbal stem cell preparations of the invention comprises one or more ingredients selected from factors and agents that promote any one or more of survival and maintenance of stem cell characteristics, growth of stem cells, and survival, maintenance and differentiation of stem cell offspring *in vitro* or *in vivo*. Such agents include EGF, basic FGF and NGF, as those factors stimulate the proliferation of limbal stem cells and their progenitors.

10

Optimal amounts, concentrations and ratios of the various ingredients of a pharmaceutical preparation of the present invention may be determined empirically, in accordance with known practice using *in vitro* and/or *in vivo* tests. Methods 15 for isolating and culturing epithelial cells *in vitro*, for example, corneal and conjunctival epithelial cells, are well known, see for example, WO98/16629. Methods of determining ocular epithelial cell growth and differentiation *in vivo* using animal models are also known, for example, the well 20 established Draize test. For ethical reasons, however, it is preferable to carry out as much validation as possible *in vitro*.

Detailed descriptions of ingredients suitable for use in 25 pharmaceutical preparations of the present invention and an indication of appropriate concentrations and other factors are given in the Examples below. The person skilled in the art is able to modify any of the parameters in accordance with any particular requirement using routine procedures and 30 common general knowledge, for example, as described above.

The pharmaceutical preparations of the present invention are suitable for administration to humans or to non-human animals, especially to humans. Non-human animals include

animals raised for food, transport, hides, hair or fleece, for example, cattle, horses, sheep, goats, pigs and birds; animals used for the production of pharmaceutically useful agents, for example, recombinant proteins; stud and breeding 5 animals; racehorses; and companion animals, for example, cats, dogs, small mammals and birds.

To comply with regulatory standards for preparations for human or veterinary use, the preparations should be free from 10 ingredients obtained from humans or animals, in particular from blood, organs and glands, unless those ingredients are licensed for pharmaceutical use. The ingredients of a pharmaceutical preparation of the present invention should be synthetic or recombinant, or licensed for pharmaceutical use. 15 Preferably the preparations should comply with the European Union transmissible spongiform encephalopathy (TSE) requirements for medicinal products as given in General Monograph 1483 and General Chapter 5.2.8 of the European Pharmacopoeia.

20

#### **Formulations**

A pharmaceutical preparation of the present invention is in a form suitable for use in the eye, for example, in the form of a solution, cream, ointment or gel.

25

Carriers suitable for use in the eye are well known and are described in pharmacopoeias. They include suitably purified water for drops, carbomer for gels, and paraffin and/or lanolin for ointments.

30

The pH of the pharmaceutical preparation is appropriate for its intended use. For example, eye drops may have a pH in the range of from 4.5 to 9.0, for example, from 6.0 to 9.0 preferably from 6.6 to 8.0, most preferably about 7.2. For

treatment or prophylaxis of dry eye an alkaline pH, for example up to about 8.5, may be preferred. The osmolarity of eye drops is generally in the range from 100 to 350 mOsm, for example, from 120 to 320 mOsm, for example, from 150 to 350 5 mOsm, for example from 290 to 320 mOsm, for example, about 305 mOsm. The same pH and osmolarity ranges are generally used for creams, gels and ointments.

The surface tension of eye drops is preferably from about 40 10 dyne/cm to about 80 dyne/cm, for example, about 60 dyne/cm.

The contact angle (wetting angle) of the eye drops is preferably from about 20° to about 50°, for example, about 30°.

15

The viscosity of the eye drops is preferably from about 5 cps to about 50 cps, for example, about 10 cps.

Pharmaceutical preparations of the present invention should 20 preferably produce clinically significant prolongation of tear break-up time (BUT). Tear BUT is dependant on tear film composition and anatomical factors, for example, lid-globe incongruity which may vary between individuals. As a general guide, a pharmaceutical preparations of the present invention 25 should, when applied at a typical dose, for example, a drop of 50 µl, result in a prolongation of BUT of at least 20 minutes, preferably, at least 40 minutes, for example, about 50 minutes.

30 In the case of a solution, the ingredients of a pharmaceutical preparation of the invention may be dissolved in the carrier and filled into appropriate containers. Single dose units may be provided, for example, single dose plastic ampoules. Other formulations, for example, gels,

creams and ointments are produced according to normal pharmaceutical practice. Such formulations may be provided in single dose units or in containers that enable single doses to be dispensed, for example, metered pumps. It may be 5 advantageous to use a solution, especially when a therapeutic agent is present in the preparation, as it is generally easier to provide a unit dose with a solution than with a cream, gel or ointment. One drop of a solution is generally about 50 $\mu$ L.

10

#### **Therapeutic utility of the pharmaceutical preparations of the present invention**

As stated above, the pharmaceutical preparations of the present invention are useful in the treatment or prophylaxis 15 and various eye conditions.

Ocular surface disorders are a group of disorders of diverse pathogenesis, in which disease results from the failure of the mechanisms responsible for maintaining a healthy ocular 20 surface. The causes of the disorder may be nutritional, traumatic, iatrogenic, proliferative, or may be secondary to lid abnormalities, may be caused by abnormal tear film, or may be neurotrophic. The defects are often resistant to healing. Some types of ocular surface disorders result from 25 or cause dry or severely dry eyes. Dry eye conditions that are not severe are generally called "dry eye" or "dry eye condition". Severely dry eyes are a condition also known as keratoconjunctivitis sicca. However, dry eye conditions may occur without causing or resulting from ocular surface 30 disorders. When part of Sjögren's syndrome, dry eye condition is often severe. Non-Sjögren's dry eye ("dry eye") is very common. Dry eye conditions, even when not associated with other pathologies, cause much discomfort and pain and predispose the eye to infection. Any condition or disorder

in which the ocular surface is not a properly functioning unit is an ocular surface disorder. Such disorders and conditions include dry eye, kerato-conjunctivitis sicca and Sjögren's syndrome, scarring, post-surgery conditions, and 5 ocular pemphigoid, persistent epithelial defect, or acute or chronic ocular surface disease.

Limbal stem cells, which occur in the limbus tissue at the junction of the cornea and the conjunctiva and/or in the 10 fornix, are the progenitors of the epithelial cells of the conjunctiva and cornea ie the ocular surface. Even partial failure of these stem cells to maintain healthy, normally differentiated ocular surface epithelial cells has severe consequences for the ocular surface.

15

An ocular surface medium of the invention, comprises (i) a pharmaceutically carrier suitable for use in the eye; (ii) one or more ingredients selected from factors and agents that promote any one or more of survival, health, cell 20 attachment and normal differentiation of ocular surface epithelial cells and, optionally, from factors and agents that prevent squamous metaplasia; (iii) one or more agents capable of altering the fluid properties of a tear film including at least one agent 25 capable of establishing and/or maintaining a stable tear film; and, optionally one or more agents selected from ophthalmological lubricating agents, viscosity enhancing agents and agents capable of reducing tear film evaporation; the factors and agents in components (ii) and (iii) being 30 synthetic or recombinant or licensed for pharmaceutical use.

By promoting any one or more of survival, health, cell attachment and normal differentiation of ocular surface epithelial cells and optionally preventing squamous

metaplasia while maintaining a stable tear film, an ocular surface medium of the invention actively promotes a normal, healthy ocular surface and may be used in treatment and/or prophylaxis of dry eye conditions and ocular surface

5 disorders. Dry eye conditions include dry eye, kerato-  
conjunctivitis sicca and Sjögren's syndrome. Ocular surface disorders include scarring, post-surgery and other post-  
trauma conditions, ocular pemphigoid, persistent epithelial defect, and acute or chronic ocular surface disease.

10

A therapeutic ocular surface medium of the invention, which comprises (iv) one or more agents suitable for use in treatment or prophylaxis of ocular surface, disorders or damage in addition to components (i) to (iii) may be used in 15 treatment or prophylaxis of ocular surface disorders and dry eye conditions in which there are or may be additional pathological conditions, for example, infection or inflammation, a neoplastic condition, trauma, or an autoimmune, degenerative, or iatrogenic condition. Further 20 examples are post-surgery and other post-trauma conditions, for example, penetrating keratoplasty in eyes with a history of persistent epithelial defect (PED) and following large conjunctival autografts.

25 A limbal stem cell medium of the invention comprises (v) one or more ingredients selected from factors and agents that promote any one or more of survival and maintenance of stem cell characteristics, growth of ocular surface stem cells, and survival, maintenance and differentiation of stem 30 cell offspring *in vitro* or *in vivo* in addition to components (i) to (iii). A limbal stem cell medium of the invention may be used in treatment or prophylaxis of conditions that involve deficiencies or failure of limbal stem cells, for example, partial or complete limbal stem cell failure, and

post-operative therapy following surgery for limbal stem cell transplantation.

A therapeutic limbal stem cell medium of the invention  
5 comprises component (iv) as defined above in addition to  
components (i) to (iii), and (v). A therapeutic limbal stem  
cell medium may be used in treatment or prophylaxis of the  
limbal stem cell conditions above in which there are or may  
be additional pathological conditions, for example, infection  
10 or inflammation, a neoplastic condition, trauma, or an  
autoimmune, degenerative, or iatrogenic condition. Further  
examples are post-surgery and other post-trauma conditions,  
for example, penetrating keratoplasty in eyes with a history  
of persistent epithelial defect (PED) and following large  
15 conjunctival autografts.

The present invention provides a pharmaceutical preparation  
of the invention for use as a medicament. The invention also  
provides the use of the various media defined above for the  
20 particular indications given as follows:

An ocular surface medium of the invention for use in  
treatment or prophylaxis of ocular surface disorders and dry  
eye conditions, including dry eye, kerato-conjunctivitis  
25 sicca and Sjögren's syndrome, scarring, post-surgery  
conditions, ocular pemphigoid, persistent epithelial defect,  
or acute or chronic ocular surface disease.

A therapeutic ocular surface medium of the invention for use  
30 in treatment or prophylaxis of ocular surface disorders and  
dry eye conditions, including dry eye, kerato-conjunctivitis  
sicca and Sjögren's syndrome, scarring, post-surgery  
conditions, ocular pemphigoid, persistent epithelial defect,  
or acute or chronic ocular surface disease in which there is

or may be additional pathological conditions, for example, infection or inflammation, a neoplastic condition, trauma, or an autoimmune, degenerative, or iatrogenic condition.

Further examples are post-surgery and other post-trauma  
5 conditions, for example, penetrating keratoplasty in eyes with a history of persistent epithelial defect and following large conjunctival autografts.

A limbal stem cell medium of the invention for use in  
10 treatment or prophylaxis of conditions that involve deficiencies or failure of limbal stem cells, for example, complete or partial limbal stem cell failure, and post-operative therapy following surgery for limbal stem cell transplantation.

15 A therapeutic limbal stem cell medium of the invention for use in treatment or prophylaxis of conditions that involve deficiencies or failure of limbal stem cells, for example, complete or partial limbal stem cell failure, and post-  
20 operative therapy following surgery for limbal stem cell transplantation, in which there is or may be additional pathological conditions, for example, infection or inflammation, a neoplastic condition, trauma, or an autoimmune, degenerative, or iatrogenic condition. Further  
25 examples are post-surgery and other post-trauma conditions, for example, penetrating keratoplasty in eyes with a history of PED large conjunctival autografts.

30 The invention also provides the use of a pharmaceutical preparation of the invention for the manufacture of a medicament for the various methods of treatment and prophylaxis set out above.

The present invention further provides methods of treatment or prophylaxis of the various conditions described above comprising applying the appropriate medium to the affected eye, see the Summary of the Invention.

5

The pharmaceutical preparations of the invention promote survival, maintenance, health, growth, migration, cell attachment and/or normal differentiation of ocular surface epithelial cells and prevent squamous metaplasia and are 10 effective in treatment of ocular surface disorders and dry eye conditions. Previously proposed "artificial tears" are ocular lubricants, which may improve tear volume and hydrodynamics but which do not promote survival, maintenance, health, growth, migration, cell attachment and/or normal 15 differentiation of ocular surface epithelial cells. Previously proposed treatments for ocular surface disorders and dry eye conditions, which include topical therapy, surgery and therapeutic contact lenses, have not proven satisfactory. Dry eye conditions, even if not severe, cause 20 much discomfort and pain and predispose the eye to infection. Such conditions are common. The pharmaceutical preparations of the present invention, in particular the ocular surface medium and the therapeutic ocular surface medium, provide simple and effective treatment and prophylaxis for such 25 conditions and for other ocular surface disorders.

The limbal stem cell media of the present invention promote survival and maintenance of stem cell characteristics, and/or growth of ocular surface stem cells, and/or survival, 30 maintenance and differentiation of stem cell offspring in addition to promoting survival, maintenance, health, growth, migration, cell attachment and/or normal differentiation of ocular surface epithelial cells and preventing squamous metaplasia. The limbal stem cell media promote the

regeneration of limbal cells and their differentiation into epithelial cells and also nurture and support the stem cells themselves and the cells into which they differentiate. The limbal stem cell media of the present invention provide 5 simple and effective treatment and prophylaxis for conditions that involve deficiencies or failure of limbal stem cells, for example, partial or complete limbal stem cell failure, and post-operative therapy following surgery for limbal stem cell transplantation.

10

**Use as a vehicle for other therapeutic agents**

A pharmaceutical preparation of the present invention may comprise a therapeutic agent, in particular a therapeutic agent that is useful for treating conditions that are or may 15 be associated with dry eye or an ocular surface condition.

In addition, the present invention provides the use of an ocular surface medium or limbal stem cell medium of the present invention as a pharmaceutical vehicle or carrier for 20 an ophthalmological pharmaceutical composition.

The present invention also provides an ophthalmological pharmaceutical composition that comprises a therapeutic agent and, as the or a pharmaceutical vehicle or carrier, an ocular 25 surface medium or limbal stem cell medium of the present invention. Such therapeutic agents include, for example, anti-microbial agents such as antibiotics, antibacterials, antifungals, antivirals and disinfectants; anti-inflammatory agents such as corticosteroids and non-steroidal anti- 30 inflammatories; anti-glaucoma agents to lower intraocular pressure such as sympathomimetics, beta-blockers, prostaglandin analogues, parasympathomimetic, and carbonic anhydrase inhibitors; mucolytics such as acetylcysteine; mydriatics and cycloplegics such as anti-muscarinics and

sympathomimetics; and anti-allergy agents such as most cell stabilisers and antihistamines.

An advantage of using a pharmaceutical preparation of the 5 present invention, in particular an ocular surface medium (OSM) or a limbal stem cell medium (LSCM) instead of a conventional carrier is that a pharmaceutical preparation of the present invention supports the one or more of survival, health, cell attachment and normal differentiation of ocular 10 surface epithelial cells while maintaining a stable tear film, thereby actively promoting a normal, healthy ocular surface and, in the case of the limbal stem cell medium, supports the growth and differentiation of the ocular surface stem cells.

15

Many ophthalmic therapeutic agents have a deleterious effect on the ocular surface, for example, some are toxic or contain preservatives that are toxic to the corneal epithelium. However, if the condition that requires treatment is 20 sufficiently severe, the risk of failure to treat the condition may outweigh possibility of damage to the ocular surface. By promoting the health and viability of the ocular surface, the use of an OSM or LSCM of the invention as a vehicle for such a therapeutic agent counteracts the adverse 25 effects of the therapeutic agent and hence reduces the risk of damage.

Benzalkonium chloride, a preservative often used in ophthalmological preparations, damages ocular surface cells. 30 However, use of that preservative cannot always be avoided. By promoting the health and viability of the ocular surface, the use of an OCS or LSCM of the invention as a vehicle for in a composition comprising benzalkonium chloride counteracts

the adverse effects of the preservative and hence reduces the risk of damage.

**Use of a pharmaceutical preparation of the invention for in 5 vitro culture of ocular surface epithelial cells**

A pharmaceutical preparation of the present invention may be used as an *in vitro* culture medium for ocular surface epithelial cells.

10 The following non-limiting Examples illustrate the invention.

**EXAMPLES**

**EXAMPLE 1**

15 **Ocular Surface Medium**

An Ocular Surface Medium was formulated as eye drops as follows:

*Preparation of Ocular Surface Medium Basic Mixture*

20 Water suitable for use in eye drops ("water") was measured out to 80% of the total desired volume. While gently stirring this water with a magnetic stirrer, the following were added: L-alanine (8.69 mg/L), L-arginine.HCl (406.70 mg/L), L-asparagine.HCl (12.74 mg/L), L-aspartic acid (3.86 mg/L), L-cysteine.HCl.H<sub>2</sub>O (40.53 mg/L), L-glutamic acid (14.28 mg/L), L-glutamine (984.40 mg/L), glycine (7.34 mg/L), L-histidine.HCl.H<sub>2</sub>O (48.64 mg/L), L-isoleucine (5.79 mg/L), L-leucine (126.60 mg/L), L-lysine.HCl (52.98 mg/L), L-methionine (13.03 mg/L), L-phenylalanine (9.65 mg/L), L-proline (33.39 mg/L), L-serine (121.80 mg/L), L-threonine (22.97 mg/L), L-tryptophan (8.98 mg/L), L-tyrosine-disodium salt (11.27 mg/L), L-valine (67.75 mg/L), biotin (0.019 mg/L), D-Ca<sup>++</sup>-pantothenate (0.29 mg/L), choline chloride (13.51 mg/L), folic acid (0.772 mg/L), *i*-inositol

(17.37 mg/L), niacinamide (0.039 mg/L), pyridoxine.HCl (0.058 mg/L), riboflavin (0.039 mg/L), thiamine.HCl (0.29 mg/L), vitamin B12 (0.396 mg/L), putrescine.2HCl (0.193 mg/L), D-glucose (1462.00 mg/L), KCl (108.10 mg/L), NaCl (6553.00 mg/L), thymidine (0.704 mg/L), adenine (23.16 mg/L), [4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid], (HEPES, 3220.00 mg/L), lipoic acid (0.193 mg/L), sodium pyruvate (53.08 g), sodium acetate (290.50 mg/L), Na<sub>2</sub>HPO<sub>4</sub> (274.10 mg/L), Na<sub>2</sub>SO<sub>4</sub> (3.38 mg/L), and recombinant human insulin (5.00 mg/L).

A stock solution of ethanolamine.HCl was prepared in water at 976 mg/L and 0.615 ml/L of this stock was added to the basic medium solution, to give a final concentration of 15 ethanolamine.HCl of 0.60 mg/L.

A stock solution of phosphoethanolamine was prepared in water at 1408.00 mg/L and 0.1001 ml/L of this stock was added to the basic medium solution, to give a final concentration of 20 phosphoethanolamine of 0.141 mg/L.

A stock solution of FeSO<sub>4</sub>.7H<sub>2</sub>O (41.70 mg/L), MgCl<sub>2</sub>.6H<sub>2</sub>O (18890 mg/L), CaCl<sub>2</sub>.2H<sub>2</sub>O and 0.207 CuSO<sub>4</sub>.5H<sub>2</sub>O (1343.5 mg/L) was prepared in water containing 0.5 ml/L concentrated HCl, and 25 9.660 ml of this stock solution was added to the basic medium solution, to give final concentrations of 0.403 mg/L FeSO<sub>4</sub>.7H<sub>2</sub>O, 182.50 mg/L MgCl<sub>2</sub>.6H<sub>2</sub>O, 12.98 mg/L CaCl<sub>2</sub>.2H<sub>2</sub>O and 0.002 mg/L CuSO<sub>4</sub>.5H<sub>2</sub>O.

30 A stock solution of ZnSO<sub>4</sub>.7H<sub>2</sub>O (137.68 mg/L) was prepared in water, and 0.9660 ml of this solution was added to the basic medium solution to give a final concentration of 0.133 mg/L ZnSO<sub>4</sub>.7H<sub>2</sub>O.

A stock solution containing  $\text{Na}_2\text{SeO}_3$  (0.513 mg/L),  $(\text{NH}_4)_6\text{Mo}_7\text{O}_{24} \cdot 4\text{H}_2\text{O}$  (0.124 mg/L),  $\text{NaSiO}_3 \cdot 9\text{H}_2\text{O}$  (14.2 mg/L),  $\text{NiSO}_4 \cdot 6\text{H}_2\text{O}$  (0.013 mg/L),  $\text{MnCl}_2 \cdot 4\text{H}_2\text{O}$  (0.002 mg/L),  $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$  (0.011 mg/L) and  $\text{NH}_4\text{VO}_3$  (0.059 mg/L) was prepared in water  
5 with 0.5 ml/L concentrated HCl, and 9.660 ml of this stock solution was added to the basic medium solution to give final concentrations of 0.00496 mg/L  $\text{Na}_2\text{SeO}_3$ , 0.00120 mg/L  $(\text{NH}_4)_6\text{Mo}_7\text{O}_{24} \cdot 4\text{H}_2\text{O}$ , 0.137 mg/L  $\text{NaSiO}_3 \cdot 9\text{H}_2\text{O}$ , 0.00013 mg/L  $\text{NiSO}_4 \cdot 6\text{H}_2\text{O}$ , 0.00002 mg/L  $\text{MnCl}_2 \cdot 4\text{H}_2\text{O}$ , 0.00011 mg/L  $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$   
10 and 0.00057 ml/L  $\text{NH}_4\text{VO}_3$ .

A stock of hydrocortisone was prepared at 370 mg/L in 95% ethanol, and 0.2 ml of this stock was added to the basic medium solution to give a final concentration of  
15 hydrocortisone of 0.074 mg/L.

A stock solution of sodium triiodothyronine (T3) was prepared at 67.00 mg/L in 70% ethanol, and 0.1 ml of this stock was added to the basic medium solution to give a final  
20 concentration of T3 of 0.0067 mg/L.

$\text{NaHCO}_3$  (1160 mg/L) was added to the basic medium solution, and the pH of the solution was then adjusted with HCl to 7.2 $\pm$ 0.25 and the volume adjusted to the full desired volume  
25 with water. The osmolality was determined to be 290 $\pm$ 15 mOsm.

The mixture was then sterile filtered through a low protein binding filter, under appropriate conditions, bottled and stored under diminished light conditions at 4°C until use.  
30

#### *Preparation of the Supplement*

To a sterile solution of Dulbecco's Phosphate Buffered Saline (DPBS) or water suitable for eye drops the following were added while gently stirring: ascorbic acid phosphate,

magnesium salt (50 mg/L), acidic FGF (2.5 mg/L), sodium salt of recombinant human heparin (5000 USP units/L) and recombinant human EGF (0.1 mg/L).

- 5 A stock solution of isoproterenol.HCl (1,000,000 mg/L) was prepared in DPBS or water containing 50 mg/L ascorbic acid, and 1.25 ml/L of this solution was added to the above, to form a 500X formulation of the supplement.
- 10 This 500X solution was then sterile filtered through a low protein binding filter, and added to the basic medium mixture or aliquotted and stored at -20 to -80°C until use.

*Preparation of the Eye Drops*

- 15 The supplement was added to the mixture of the basic medium at a ratio of 1:500 by volume for use as eye drops. The resulting eye drops were stored at 4°C under diminished light conditions until use.
- 20 The drops may be used every two hours (eight times per day).

**EXAMPLE 2**

- A pharmaceutical preparation having the formulation given in Example 1 was tested by three healthy volunteers. Drops of 25 the solution were administered to the eye every 2 hours (eight times per day) hours for up to a week. No adverse reactions occurred. The drops were described as "comfortable".

**30 EXAMPLE 3**

**Ocular Surface Medium**

The data below gives a list of components for an ocular surface medium for treatment of dry eye which medium is an alternative to that given in Example 1. Preferred

concentrations of each component and an approximate indication of a preferred range of concentrations of each component are given. Such a medium was made up in a similar way to that exemplified in Example 1.

5

MEDIUM Component	Concentration (mg/litre)	Range (mg/litre)
<u>Proteins</u>		
Lysozyme	3000	200-6900
Lactoferrin	2000	400-3400
sIgA	1000	20-4500
Tri-iodothyronine Sodium	0.0067	± 0.0003
Zinc Insulin Human	5	± 0.3
<u>Amino Acids</u>		
<i>Essential amino acids</i>		
L-Arginine. Hydrochloride	406.7	± 20.3
L-Cysteine. Hydrochloride. H <sub>2</sub> O	40.53	± 2.03
L-Glutamine	984.4	± 49.2
L-Histidine Hydrochloride. H <sub>2</sub> O	48.64	± 2.43
L-Isoleucine	5.79	± 0.29
L-Leucine	126.6	± 6.3
L-Lysine Hydrochloride	52.98	± 2.65
L-Methionine	13.03	± 0.65
L-Phenylalanine	9.65	± 0.48
L-Threonine	22.97	± 1.15
L-Tryptophan	8.98	± 0.45
L-Valine	67.75	± 3.39
<i>Non-essential amino acids</i>		
L-Alanine	8.69	± 0.43
Glycine	7.34	± 0.37
L-Asparagine	12.74	± 0.64
L-Aspartic Acid	3.86	± 0.19
L-Glutamic Acid	14.28	± 0.71
L-Proline	33.39	± 1.67
L-Serine	121.8	± 6.1
Taurine	143.75	± 7.20
L-Tyrosine Disodium	11.27	± 0.56

Component	Concentration (mg/litre)	Range (mg/litre)
<u>Vitamins</u>		
Ascorbic Acid-2-Phosphate	50	± 3
Biotin	0.019	± 0.001
Folic Acid	0.772	± 0.039
Niacinamide	0.039	± 0.002
D-Calcium Pantothenate	0.29	± 0.02
Pyridoxine. Hydrochloride	0.058	± 0.003
Riboflavin	0.039	± 0.002
Thiamine. Hydrochloride	0.29	± 0.0015
Vitamine B <sub>12</sub>	0.396	± 0.020
<u>Antioxidents</u>		
L-tyrosine disodium	see amino-acids	
Taurine	See amino-acids	
Glutathione	32.88	± 1.64
Lipoic Acid	0.193	± 0.097
<u>Carbohydrate</u>		
D-Glucose	1462	± 146
<u>Lipids</u>		
Phosphorylethanolamine	0.141	± 0.007
Ethanolamine	0.6	± 0.03
<u>Electrolytes</u>		
<b>Bulk Inorganic ions</b>		
Sodium Chloride	6553	± 328
Potassium Chloride	108.1	± 5.4
Sodium Sulphate	3.38	± 0.17
Calcium Chloride. 2H <sub>2</sub> O	3.54	± 0.18
Sodium Bicarbonate	1160	± 116
Magnesium Chloride. 6H <sub>2</sub> O	182.5	± 9.1
Disodium Phosphate Dibasic	274.1	± 13.7
<u>Trace elements</u>		
Cupric Sulphate. 5H <sub>2</sub> O	0.002	± 0.0001
Ferrous Sulphate. 7H <sub>2</sub> O <sup>+</sup>	0.403	± 0.02
Manganese Chloride. 4H <sub>2</sub> O	0.00002	± 0.000001

Component	Concentration (mg/litre)	Range (mg/litre)
Ammonium Molybdate. 4H <sub>2</sub> O	0.001	± 0.00005
Nickel Sulphate. 6H <sub>2</sub> O	0.00013	± 0.00001
Sodium Selenite	0.005	± 0.00025
Sodium Metasilicate. 9H <sub>2</sub> O	0.137	± 0.007
Stannous Chloride. 2H <sub>2</sub> O	0.00011	± 0.00001
Ammonium Metavanadate	0.00057	± 0.00003
Zinc Sulphate. 7H <sub>2</sub> O	0.133	± 0.003
<u>Other organic components</u>		
Sodium Acetate	290.5	± 14.5
Adenine	23.16	± 1.16
Choline Chloride	13.51	± 0.68
i-Inositol	17.37	± 0.87
Linoleate		
Putrescine. Dihydrochloride	0.193	± 0.010
Sodium Pyruvate	53.08	± 2.65
Thymidine	0.704	± 0.035
<u>Protease inhibitors</u>		
Tissue inhibitors of matrix	50	± 50
Metalloproteinases (TIMPs)		
<u>Other therapeutic agents</u>		
Hydrocortisone	0.074	± 0.004
<u>Excipients</u>		
<b>Buffers</b>		
HEPES Ultra Pure	3220	± 322
Bicarbonate	As needed to adjust pH	See physical properties
<b>Tonicity agents</b>		
Glucose	As needed to adjust tonicity	See physical properties
Sodium chloride	As needed to adjust tonicity	See physical properties

SUPPLEMENT FOR 1:500 DILUTION IN MEDIUM

Component	Concentration (mg/litre)	Range (mg/litre)
<u>Vitamin</u>		
Ascorbic Acid 2-Phosphate	500	± 25
<u>Growth Factors</u>		
Recombinant EGF Human	0.2	± 0.02
Recombinant HGF Human	5	± 0.25
Recombinant KGF Human	5	± 0.25
Acidic FGF Human	2.5	± 0.1
<u>Other therapeutic agents</u>		
Isoproterenol Hydrochloride	125	± 6
<u>Electrolytes</u>		
<i>Bulk Inorganic ions</i>		
Sodium Chloride	8000	± 400
Potassium Chloride	200	± 10
Sodium Phosphate Dibasic	2160	± 108
Potassium Phosphate Monobasic	200	± 10

The above medium when made in accordance with this example and with the supplement added at a 1:500 dilution had the 5 measured physical properties listed below. Also listed are ranges of acceptable values.

Property	Measured values	Acceptable Range
Osmolality (Osmotic pressure)	305 mOsm/kg (= 0.95% sodium chloride)	290-320 mOsm/kg
pH	7.2	6.6-8
Surface tension	60 dyne/cm	40-80 dyne/cm
Prolongation of BUT	50	40-90 minutes
Angle of contact	30°	20-50°
Viscosity	10 cps	5-50 cps
Dose (single eye drop)	50 microlitres	± 15

**EXAMPLE 4**

The data given below gives a list of components for a further alternative ocular surface medium for treatment of dry eye. Such a medium was made up in a similar way to that 5 exemplified in Example 1.

**MEDIUM**

**Component**

**Preferred  
Concentration  
(mg/litre)**

**Acceptable  
Range  
(mg/litre)**

Proteins

Tri-iodothyronine Sodium	0.0067	± 0.0003
Zinc Insulin Human	5	± 0.3

Amino Acids

*Essential amino acids*

L-Arginine. Hydrochloride	406.7	± 20.3
L-Cysteine. Hydrochloride. H <sub>2</sub> O	40.53	± 2.03
L-Glutamine	984.4	± 49.2
L-Histidine. Hydrochloride. H <sub>2</sub> O	48.64	± 2.43
L-Isoleucine	5.79	± 0.29
L-Leucine	126.6	± 6.3
L-Lysine. Hydrochloride	52.98	± 2.65
L-Methionine	13.03	± 0.65
L-Phenylalanine	9.65	± 0.48
L-Threonine	22.97	± 1.15
L-Tryptophan	8.98	± 0.45
L-Valine	67.75	± 3.39

*Non-essential amino acids*

L-Alanine	8.69	± 0.43
Glycine	7.34	± 0.37
L-Asparagine	12.74	± 0.64
L-Aspartic Acid	3.86	± 0.19
L-Glutamic Acid	14.28	± 0.71
L-Proline	33.39	± 1.67
L-Serine	121.8	± 6.1

Component	Concentration (mg/litre)	Range (mg/litre)
L-Tyrosine Disodium	11.27	± 0.56
<u>Vitamins</u>		
Ascorbic Acid-2-Phosphate	50	± 3
Biotin	0.019	± 0.001
Folic Acid	0.772	± 0.039
Niacinamide	0.039	± 0.002
D-Calcium Pantothenate	0.29	± 0.02
Pyridoxine. Hydrochloride	0.058	± 0.003
Riboflavin	0.039	± 0.002
Thiamine. Hydrochloride	0.29	± 0.0015
Vitamine B <sub>12</sub>	0.396	± 0.020
<u>Antioxidants</u>		
L-Tyrosine Disodium	see amino-acids	
Lipoic Acid	0.193	± 0.097
<u>Carbohydrate</u>		
D-Glucose	14.62	± 14.6
<u>Lipids</u>		
Phosphorylethanolamine	0.141	± 0.007
Ethanolamine	0.6	± 0.03
<u>Electrolytes</u>		
<i>Bulk inorganic ions</i>		
Sodium Chloride	6553	± 328
Potassium Chloride	108.1	± 5.4
Sodium Sulphate	3.38	± 0.17
Calcium Chloride. 2H <sub>2</sub> O	3.54	± 0.18
Sodium Bicarbonate	1160	± 116
Ferrous Sulphate. 7H <sub>2</sub> O	0.403	± 0.02
Magnesium Chloride. 6H <sub>2</sub> O	182.5	± 9.1
Disodium Phosphate Dibasic	274.1	± 13.7
<u>Trace elements</u>		
Cupric Sulphate 5H <sub>2</sub> O	0.002	± 0.0001
Ferrous Sulphate. 7H <sub>2</sub> O	0.403	± 0.02
Manganese Chloride. 4H <sub>2</sub> O	0.00002	± 0.000001
Ammonium Molybdate. 4H <sub>2</sub> O	0.001	± 0.00005

Component	Concentration (mg/litre)	Range (mg/litre)
Nickel Sulphate. 6H <sub>2</sub> O	0.00013	± 0.00001
Sodium Selenite	0.005	± 0.00025
Sodium Metasilicate. 9H <sub>2</sub> O	0.137	± 0.007
Stannous Chloride. 2H <sub>2</sub> O	0.00011	± 0.000006
Ammonium Metavanadate	0.00057	± 0.00003
Zinc Sulphate. 7H <sub>2</sub> O	0.133	± 0.003
<u>Other organic components</u>		
Sodium Acetate	290.5	± 14.5
Adenine	23.16	± 1.16
Choline Chloride	13.51	± 0.68
i-Inositol	17.37	± 0.87
Putrescine. Dihydrochloride	0.193	± 0.010
Sodium Pyruvate	53.08	± 2.65
Thymidine	0.704	± 0.035
<u>Other therapeutic agents</u>		
Hydrocortisone	0.074	± 0.004
<u>Excipients</u>		
<b>Buffers</b>		
HEPES Ultra Pure	3220	± 322
Bicarbonate	see electrolytes	
<b>pH Indicator</b>		
Phenol Red	1.158	± 0.058
<b>Tonicity agents</b>		
Glucose	see carbohydrate	
Sodium chloride	see electrolytes	

**SUPPLEMENT FOR 1:500 DILUTION IN MEDIUM**

Component	Concentration (mg/litre)	Range (mg/litre)
<u>Vitamins</u>		
Ascorbic Acid 2-Phosphate	50	± 2.5
<u>Growth factors</u>		
Recombinant EGF Human	0.10	± 0.01
Recombinant Acidic FGF	2.5	± 0.1
<u>Other therapeutic agents</u>		
Isoproterenol Hydrochloride	125	± 6

Component	Concentration (mg/litre)	Range (mg/litre)
<u>Electrolytes</u>		
<u>Bulk inorganic ions</u>		
Sodium Chloride	8000	± 400
Potassium Chloride	200	± 10
Sodium Phosphate Dibasic	2160	± 108
Potassium Phosphate	200	± 10

**EXAMPLE 5**

**Ocular Surface Repair Medium**

5 The data below gives a list of components for a therapeutic ocular surface repair medium particularly suitable for the treatment of the following:

- Persistent epithelial defect
- Acute or chronic ocular surface disease

10 • Post-operative treatment of penetrating keratoplasty in eyes with history of PED and post-operative treatment of large conjunctival autografts

The composition of both the medium and the supplement is as  
15 given in Example 3 with the following variations and additions:

**MEDIUM**

Component	Concentration (mg/l)	Range (mg/litre)
<u>Vitamins</u>		
Vitamin C (ascorbic acid)	100000	± 5000
<u>Proteinase inhibitors</u>		
Tissue inhibitors of matrix	50	± 50
Metalloproteinases (TIMPs)		

**SUPPLEMENT FOR 1:500 DILUTION IN MEDIUM**

Growth Factors

Recombinant EGF Human	0.5	± 0.05
Recombinant HGF Human	5	± 0.25
Recombinant KGF Human	5	± 0.25
Recombinant Acidic FGF	2.5	± 0.1
Recombinant Anti-TGFbeta e.g. CAT-152 antibody Human	10	± 0.5
Neurotrophins		

NGF	100	20-200
GDNF	100	± 5

Attachment factors

Fibronectin	500	100-3500
-------------	-----	----------

Other therapeutic agents

Isoproterenol Hydrochloride	125	± 6
-----------------------------	-----	-----

Electrolytes

***Bulk inorganic ions***

Sodium Chloride	8000	± 400
Potassium Chloride	200	± 10
Sodium Phosphate Dibasic	2160	± 108
Potassium Phosphate	200	± 10
Monobasic		

**EXAMPLE 6**

**Limbal stem cell medium**

5 The data below gives a list of components for a medium for treatment of limbal stem cell failure or dysfunction and post-operative limbal stem cell transplant

The composition of both the medium and the supplement is as given in Example 3 with the following additions and

10 variations:

**MEDIUM**

<b>Component</b>	<b>Concentration</b> (mg/litre)	<b>Range</b> (mg/litre)
<u>Vitamins</u>		
Vitamin A (retinoic acid)	500	± 25
<u>Proteinase inhibitors</u>		
Tissue inhibitors of matrix	50	± 50
Metalloproteases (TIMPs)		

**SUPPLEMENT**

Growth Factors

Recombinant EGF Human	0.2	± 0.02
Recombinant HGF Human	5	± 0.05
Recombinant KGF Human	5	± 0.05
Recombinant Basic FGF Human	2.5	± 0.1
Recombinant Anti-TGF beta e.g. CAT-152 human antibody	10	± 1

Other therapeutic agents

Isoproterenol Hydrochloride	125	± 6
-----------------------------	-----	-----

Electrolytes

**Bulk inorganic ions**

Sodium Chloride	8000	± 400
Potassium Chloride	200	± 10
Sodium Phosphate Dibasic	2160	± 108
Potassium Phosphate Monobasic	200	± 10

**5 EXAMPLE 7**

**Dry eye clinical trial**

The clinical trial described in this Example demonstrates the efficacy of an ocular surface medium made in accordance with the present invention in the treatment of dry eye.

**10 Patient data**

**Study population**

10 patients were recruited from Corneal and External disease clinics at Moorfields Eye Hospital with moderate

to severe dry eye. 8 patients were female and 2 patients were male. Both eyes of each patient were used in the trial.

Age: 52.90 ± 18.45 years

5 range 18-77  
- median 53

No patients were lost to follow-up and none withdrew from the study.

10 The disease profiles of the patients were as follows:

Sjögren's syndrome

Primary (1) and secondary (5)

15 Non-Sjögren's aqueous tear deficiency (5)

Systemic diseases

Rheumatoid arthritis (5)

Ocular Cicatricial Pemphigoid (OCP) (1)

Steven-Johnson syndrome (3)

20 Atopy (1)

Other autoimmune disease (2)

Systemic therapy

Corticosteroids, oral (1)

Immunosuppression, oral (2)

25 Corneal graft in study eye

Penetrating (2)

### Methods

#### *Clinical scoring*

30 Clinical condition of the study eyes were assessed by the following techniques:

*Rose Bengal staining:* Rose Bengal was instilled into the eyes. The eyes were divided up into 6 standardized regions and each region was given a score from 0 to 3 on the basis of the condition of that region with a score of 0 being the best 5 and a score of 3 being the worst. The scores for the regions of each eye were then added together to give a total score for each eye out of a possible total score of 18.

*Fluorescein staining:* Fluorescein was instilled into the 10 eyes. The eyes were divided up into 5 standardised regions and each region was given a score from 0 to 3 on the basis of the condition of that region with a score of 0 being the best and a score of 3 being the worst. The scores for the regions of each eye were then added together to give a total score 15 for each eye out of a possible total score of 15.

*Schirmer's test:* Schirmer's test was carried out for 5 minutes without anaesthetic. The length of a strip of wet filter paper by tears during this time was recorded in mm.

20 *Tear break-up time (BUT):* The time for a dry spot to appear on the ocular surface following a full blink was measured with a stop watch and recorded in seconds.

25 *Symptom score:* Patients were asked to score the severity of symptoms on the following scale:

Grade 0: No symptoms.

Grade 1: Symptoms were mild and they did not make me uncomfortable.

30 Grade 2: Symptoms were moderate and they did make me uncomfortable, but did not interfere with my activities.

Grade 3: Symptoms were severe and they did make me uncomfortable, but did not interfere with my activities.

Grade 4: Symptoms were very severe, they did make  
5 uncomfortable and they did interfere with my activities.

The following symptoms were scored:

10 Dryness

Foreign body sensation (sensation of sand or gravel in the eye)

Blurred vision

Discomfort

15 Photophobia

The scores for each symptom were added together to give a total symptom score out of a possible total score of 20.

20 *Facial analogue score (face score):* The patient was shown a series of 10 faces ranging from "happy" (scoring 1 point) to "sad" (scoring 10 points) and asked "which face best describes your condition?".

25 *Conjunctival injection:* The level of conjunctival injection ("blood shot eyes") was graded from 0 to 4, grade 4 being the most severe, in accordance with the Corneal and Contact Lens Research Unity (CCLRU) grades.

30 *Blepharitis:* A score out of a total possible score of 12 was calculated for each eye based on the number of symptoms noted in each eye. Each symptom scored 1 point. The symptoms observed were:

Anterior lid margin:      Grease  
                                 Skin scales  
                                 Collarettes  
                                 Frank ulcers  
5                              Loss of lashes  
                                 Inflammation

Posterior lid margin:      Cheesey secretions  
                                 Blocked glands  $>\frac{1}{3}$   
10                              Telangiectasia  
                                 Meibomitis  
                                 Notched lid margin  
                                 Active chalazia

15 *Intra Ocular Pressure (IOP)*: IOP was measured and recorded as mmHg.

*Best Corrected Visual Acuity (BCVA)*: BCVA was measured and scored as follows:

20  
1   =   6/6  
2   =   6/9  
3   =   6/12  
4   =   6/18  
25 5   =   6/24  
6   =   6/36  
7   =   6/60  
8   =   3/60  
9   =   1/60  
30 10   =   HM, CF  
11   =   PL  
12   =   NPL

*Baseline findings*

RB staining	12.9 ± 4.77	(mean ±SD)	range 5-18	median 13.5
Fluorescein	11.2 ± 3.88	(mean ±SD)	range 6-15	median 12.5
Schirmer's	1.20 ± 1.398	(mean ±SD)	range 0-4	median 1
BUT	1.20 ± 0.919	(mean ±SD)	range 0-3	median 1
Symptom score	15.60 ± 3.502	(mean ±SD)	range 9-20	median 15
Face score	7.33 2.062	(mean ±SD)	range 3-9	median 8
Conjunctival injection	3.0 ± 0.816	(mean ±SD)	range 2-4	median 3
Blepharitis	1.90 ± 1.449	(mean ±SD)	range 0-4	median 2
IOP	14.0 ± 5.696	(mean ±SD)	range 7-26	median 13
BCVA	5.20 ± 3.458	(mean ±SD)	range 1-10	median 5

RB = Rose Bengal, BUT = prolongation of tear break-up time,

IOP = Intra Ocular Pressure, BCVA = best corrected visual

5 acuity, Schirmer's = Schirmer's test.

**Intervention**

The ocular surface medium of Example 1 administered to both eyes eight times per day for one month. Patients were 10 assessed for subjective symptoms and objective signs on enrolment, week one, week 2 and on completion of trial at week 4.

Analysis

15 Changes in subjective and objective variables from baseline were analysed. The data were analysed on an "intent to treat" basis. For efficacy variables only the data from the worse eye was analysed. The worse eye was defined as that with the lowest score in Schirmer's test and the worse sum of 20 corneal and conjunctival staining. If both eyes are similar the right was used.

All safety analyses included both eyes.

The Wilcoxon rank-sum test was used to assess differences  
5 between the 2 groups with respect to change from baseline in  
all primary and secondary efficacy variables at each follow-  
up visit.

Quantitative data was analysed by paired sample t-tests for  
10 the parametric data. Independent non-parametric data was  
analysed via a Mann-Whitney U test to compare 2 groups.

## Results

### Primary outcome

15 Improvement in rose Bengal (RB) staining by 3 or more points  
from the baseline to completion of trial at week 4 in study  
eye (worse eye at baseline) was found in 7 of 10 patients in  
the study eye.

### Secondary outcomes

20 Subjective symptoms of dry eye were improved in all 10  
patients. Significant improvement from enrolment to week 4  
was seen for dryness for foreign body sensation, discomfort,  
photophobia and face score. No significant change from  
25 enrolment to week 4 was seen for blepharitis score, tear film  
break-up time prolongation, fluorescein staining score,  
Schirmer's test and intra ocular pressure (IOP).

**Wilcoxon signed rank test for paired samples**

**Symptoms** in study eye, enrolment visit compared to baseline

Symptom in study eye	Improved (n)	No change (n)	Worse (n)	p
Dryness	7	3	0	0.0104
FB sensation	8	0	2	0.0073
Blurred vision	1	3	6	0.3809
Discomfort	7	0	3	0.0106
Photophobia	7	1	2	0.0289
Global symptom	10	0	0	0.0049
Face score	8	0	1	0.0089

**Signs** in study eye, enrolment visit compared to baseline

Sign in study eye	Improved (n)	No change (n)	Worse (n)	p
BCVA	2	3	5	0.7404
Fluorescein	4	1	5	0.1232
Rose Bengal	9	1	0	0.0122
Schirmers	3	4	3	0.599
BUT	2	6	2	1.0
IOP	4	2	4	0.889
Conjunctival injection	7	3	0	0.008
Blepharitis	5	1	4	0.952

5

**Successful cases** (RB score improved by 3 or more points from enrolment to week 4)

Patients with rheumatoid arthritis (5) and also with Sjögren's syndrome secondary (3)

10 Steven-Johnson syndrome (2)

Schirmer's test (length of filter paper strip wet by tears given in mm) 0mm (2), 1mm (2), 2mm (1), 3mm (1), 4 mm (1)

**Failure cases** (RB score showed improvement of less than 3 points from enrolment to week 4)

Patients with OCP (1). Female age 54 on systemic immunosuppression. Schirmer's 0m. RB score in study eye was 16 and change in RB score was 2.

10 Steven-Johnson's syndrome and atopy (1). Female 18 years old. Schirmer's 0. RB score in study eye was 9 and change in RB score was -3.

Primary Sjögren's syndrome (1). Female age 39 years. Schirmer's was 1mm. RB score in study eye was 14 and change in RB score was 2.

15

Safety data (analysed in both eyes with Wilcoxon Signed Ranks test)

BCVA: No significant change in best-corrected visual acuity from baseline to week 4 in study eye ( $p = 0.891$ ) or in fellow eye ( $p = 0.705$ ).

IOP: No significant change in IOP from baseline to week 4 in study eye ( $p = 0.889$ ) or in fellow eye ( $p = 0.482$ ).

Conjunctival injection: Significantly reduced from baseline to week 4 in study eye ( $p = 0.008$ ) and in fellow eye ( $p = 0.014$ ).

Cataract: No patients developed cataract during the study period in the study or fellow eye. One patient underwent cataract extraction and intraocular lens implantation in the fellow eye during the trial without alteration to the topical or systemic ocular therapy.

Adverse events: One patient complained of blurred vision and discomfort whilst reading at week 2 and 3, the trial was continued and the symptoms resolved.

5 Conclusion

A subjective improvement was seen in all 10 patients and 7 of these patients had signs of an objective improvement. There were no serious adverse events and no significant change in visual acuity, intraocular pressure nor lens opacity. The 10 application of an ocular surface medium in accordance with the present invention was thus found to be an efficacious and safe therapy for ocular surface disorders.

CLAIMS:

1. A pharmaceutical preparation suitable for use in the eye, which comprises:

5 (i) a pharmaceutically carrier suitable for use in the eye;

(ii) one or more ingredients selected from factors and agents that promote any one or more of survival, health, cell attachment and normal differentiation of ocular surface 10 epithelial cells and optionally factors and agents that prevent squamous metaplasia;

(iii) one or more agents capable of altering the fluid properties of a establishing tear film including at least one agent capable of establishing and/or maintaining a stable 15 tear film and optionally one or more agents selected from ophthalmological lubricating agents, viscosity enhancing agents and agents capable of reducing tear film evaporation;

the factors and agents in components (ii) and (iii) being synthetic or recombinant or licensed for pharmaceutical 20 use.

2. A pharmaceutical preparation as claimed in claim 1, further comprising:

(iv) one or more agents suitable for use in the 25 treatment or prophylaxis of an ocular surface disease, disorder or damage.

3. A pharmaceutical preparation as claimed in claim 1 or claim 2, further comprising:

30 (v) one or more ingredients selected from factors and agents that promote any one or more of survival and maintenance of stem cell characteristics, growth of ocular surface stem cells, and survival, maintenance and differentiation of stem cell offspring *in vitro* or *in vivo*,

the factors and agents being synthetic or recombinant or licensed for pharmaceutical use.

4. A pharmaceutical preparation as claimed in claim 2 or 5 claim 3, wherein the one or more of the agents (iv) suitable for use in the treatment or prophylaxis of an ocular surface disease, disorder or damage is selected from:

mydriatics agents, steroids, mucolytic agents, inhibitors of angiogenesis, attachment factors, antifibrotic 10 agents, antimicrobial agents, anti-glaucoma agents, and agents that reduce the accumulation of toxic by-products of cell metabolism.

5. A pharmaceutical preparation as claimed in any one of 15 claims 1 to 4, wherein component (i) comprises one or more agent selected from:

purified water for eye drops, cream bases for ophthalmological compositions, gel bases for ophthalmological compositions and ointment bases for ophthalmological 20 compositions.

6. A pharmaceutical preparation as claimed in any one of claims 1 to 5, wherein component (ii) comprises one or more agent selected from:

25 agents that provide a metabolisable source of carbon, amino acids, growth factors, vitamins, antioxidants, mucin substitutes, bulk ions, trace elements, proteins, hormones, protease inhibitors, and anti-microbial agents.

30 7. A pharmaceutical preparation as claimed in any one of claims 1 to 6, wherein an agent capable of establishing and/or maintaining a stable tear film is selected from:

lipids, lipoproteins and meibomian gland secretions, and synthetic analogues thereof.

8. A pharmaceutical preparation as claimed in any one of claims 1 to 7, wherein component (iii) comprises an ophthalmological lubricating agent, a viscosity enhancing agent or an agent capable of reducing tear film evaporation selected from:

hypromellose, Semisynthetic cellulose derivatives, methylcellulose, hydroxypropylmethylcellulose, carbomer, carmellose, polyvinyl alcohol, polyacrylic acid, povidone, 10 dextran solutions, hyaluronic acid and chondroitin sulphate.

9. A pharmaceutical preparation as claimed in any one of claims 1 to 8, which does not contain benzalkonium chloride.

15 10. A pharmaceutical preparation as claim in any one of claims 1 to 9, which comprises an anti-microbial agent selected from:

lactoferrin, lysozyme, defensin and sIgA; so that the preparation may be kept at 4 degrees Celsius for 20 up to one month without microbial contamination.

11. A pharmaceutical preparation according to any one of claims 1 to 10, which has a pH in the range of from 6.6 to 8.0.

25

12. A pharmaceutical preparation as claimed in any one of claims 1 to 11, which is in the form of a solution for use as eye drops.

30 13 A pharmaceutical preparation as claimed in any one of claims 1 to 11, which is in the form of a cream, ointment or gel.

14 A pharmaceutical preparation as claimed in claim 12, wherein said solution for use as eye drops has an osmolarity in the range of from 290 mOsm to 320mOsm.

5 15. A pharmaceutical preparation as claimed in claim 12 or claim 14, wherein said solution for use as eye drops has a surface tension in the range of from 40 dyne/cm to 80 dyne/cm.

10 16. A pharmaceutical preparation as claimed in claim 12, claim 14 or claim 15, wherein said solution for use as eye drops has a viscosity in the range of from 5 cps to 50 cps.

17. A pharmaceutical preparation as claimed in any one of 15 claims 1 to 16 in a single dose container.

18. A pharmaceutical preparation as claimed in any one of claims 1 to 17 for use as a medicament.

20 19. A pharmaceutical preparation as claimed in claim 18, wherein said medicament is for the treatment of an ocular surface disorder.

20. A pharmaceutical preparation as claimed in claim 19, 25 wherein said ocular surface disorder is selected from: dry eye, severely dry eye, scarring, ocular pemphigoid, persistent epithelial defect, acute ocular surface disease, chronic ocular surface disease, infection or inflammation of the eye, neoplastic conditions of the eye and trauma to the 30 eye.

21. Use of a pharmaceutical preparation as claimed in any one of claims 1 to 17 for the manufacture of a medicament for the treatment of a condition defined in claim 19 or claim 20.

22. A method of treating an ocular surface disorder in a subject in need of such treatment comprising administering a therapeutically effective amount of a pharmaceutical preparation as claimed in any one of claims 1 to 17.

5

23. A method as claimed in claim 22, wherein the ocular surface disorder is as defined in claim 20.

10 24. A method as claimed in claim 22 or claim 23, wherein the subject is a mammal.

15

25. A method as claimed in claim 24, wherein the mammal is a human.

26. Use of a pharmaceutical preparation according to any of one claims 1 to 17 as a pharmaceutical vehicle or carrier for an ophthalmological pharmaceutical composition.

20 27. A pharmaceutical preparation as described herein with reference to any one or more of the examples.



